Roche to discontinue enfuvirtide (T-20, Fuzeon)

After many years of extremely low use, Roche Pharmaceuticals is planning to discontinue manufacturing enfuvirtide (T.-20, Fuzeon).

This decision has been made as a result of the availability of alternative therapies, which have resulted in the usage of this medicine becoming extremely limited.

At one time this twice-daily injectable entry inhibitor was a life-saving option that was used in combination with other ARVs to help overcome multiple drug resistant HIV.

Roche UK will continue to have Fuzeon available to purchase until the end of 2024 or
upon exhaustion of stock. This includes 90 mg/mL powder and solvent for solution for injection

Please contact Roche before the end of March 2024 to order special bridging stocks: welwyn.rx_bdop@roche.com

These requirements will be factored into their final replenishment order. After this time they will be unable to make any further orders.

comment

Even when demand for T-20 significantly declined with the approval of darunavir, etravirine and raltegravir, which provided new drugs and classes to overcome resistance to earliest NNRTIs and PIs, Roche stood by their commitment to continue to supply T-20, if still needed.

To have continued this for so many years is notable as many other companies might have withdrawn this drug much earlier.